China lifts some pricing restrictions

Share this article:

Poor quality and drug shortages appear to be behind China's recent decision to end price caps on some low-cost drugs. The Wall Street Journal reports that the change will affect 280 medications made by Western drug companies and will have an impact on items including antibiotics, painkillers and vitamins.

The WSJ notes that China has put significant pressure on prices in an effort to keep health costs down, which encouraged manufacturers to either stop making drugs because of the lack of profit (which is what happened with thyroid medication Tapazole), or swap in cheaper ingredients, such as industrial gelatin—a carcinogen—instead of pharma-grade gelatin to save money.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.